Analyst Ratings January 27, 2026

Evercore Lowers Altimmune Price Target to $22, Stays Constructive on Pemvidutide Progress

Analyst trims valuation amid model reset even as clinical and regulatory milestones advance and management transition is announced

By Jordan Park ALT
Evercore Lowers Altimmune Price Target to $22, Stays Constructive on Pemvidutide Progress
ALT

Evercore ISI reduced its price target on Altimmune to $22 from $25 while retaining an Outperform rating, following a comprehensive model revision since initiating coverage. The firm cites continued conviction in pemvidutide - a GLP-1/Glucagon candidate for metabolic dysfunction-associated steatohepatitis (MASH) - based on 24-week and updated 48-week data, recent regulatory interactions and breakthrough therapy designation. Altimmune also disclosed a planned CEO transition with the chairman set to assume the role.

Key Points

  • Evercore ISI reduced its Altimmune price target to $22 from $25 while maintaining an Outperform rating after a comprehensive model overhaul.
  • Pemvidutide, a GLP-1/Glucagon candidate for MASH, showed 48-week non-invasive trends suggesting fibrosis improvement and non-plateauing placebo-adjusted weight loss of 7% at the 1.8 mg dose; Phase 3 will test 2.4 mg.
  • Pemvidutide received Breakthrough Therapy Designation and Altimmune has met with the FDA to align on Phase 3 design; a planned CEO transition will see the chairman take over by January 1, 2026.

Evercore ISI has cut its price target for Altimmune Inc. (NASDAQ: ALT) to $22.00 from $25.00 but kept an Outperform rating on the stock, reflecting a recalibration of the firm's valuation model rather than a change in its overall stance toward the company. Analyst Michael DiFiore said the firm has fully reworked its modeling for Altimmune since taking coverage last year.

The adjustment comes against a backdrop of meaningful clinical and corporate developments for Altimmune. Shares of ALT were trading at $5.66 at the time of the report, having climbed 33.81% over the prior week and 56.79% year-to-date, according to the data cited by the firm. Analyst price targets on ALT span a wide range - from $1 to $28 - with the consensus recommendation generally skewing toward "Buy."

Evercore's sustained positive view centers on pemvidutide, Altimmune's investigational GLP-1/Glucagon agent. The firm characterizes the drug's mechanism as making "complete sense" for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). That endorsement comes despite what Evercore described as "placebo-driven shortcomings" observed in the 24-week readout from the Phase 2 IMPACT trial.

Altimmune subsequently released updated 48-week data derived from non-invasive testing, which Evercore flagged as showing trends suggestive of fibrosis improvement. The 48-week dataset additionally showed continued, non-plateauing weight loss at the highest dose evaluated in the trial - a placebo-adjusted decline of 7% at the 1.8 mg dose - and the company plans to evaluate a 2.4 mg dose in the forthcoming Phase 3 program.

Regulatory engagement and expedited review pathways have also moved forward. Pemvidutide received Breakthrough Therapy Designation, and Altimmune has held discussions with the U.S. Food and Drug Administration to align on the design of the Phase 3 trial. Evercore points to these events as reasons it remains constructive on the asset despite the downward revision to its target.

On the corporate governance front, Altimmune announced a leadership transition plan. Chief Executive Officer Vipin Garg is scheduled to step down by January 1, 2026. Jerry Durso, currently the company's Chairman, will assume the CEO role while retaining his chairmanship. Garg will continue to support the company as an advisor through June 30, 2026, to facilitate the handover.

Evercore's model reset, ongoing clinical readouts and regulatory interactions together shaped the firm's updated valuation. The market reaction has been notable in the short term, as evidenced by the recent share-price appreciation, while analyst targets remain dispersed, signaling a range of views on the program's ultimate commercial and clinical potential.


Clinical catalyst - Pemvidutide's mechanism and 24-week IMPACT results prompted interest, and 48-week non-invasive data showing fibrosis trends and ongoing weight loss at higher doses underpins the program heading into Phase 3.

Regulatory progress - Breakthrough Therapy Designation and FDA alignment talks are in place to inform the Phase 3 design.

Corporate transition - Management will change, with the chairman set to become CEO and the incumbent CEO serving as advisor through mid-2026 to ensure continuity.

Risks

  • The 24-week IMPACT Phase 2 results contained what Evercore described as "placebo-driven shortcomings," indicating efficacy signals may be ambiguous in shorter-duration data - this impacts biotech and healthcare investors focused on clinical-readout risk.
  • Analyst price targets for ALT range widely from $1 to $28, reflecting substantial valuation uncertainty in the market and differing interpretations of the clinical and regulatory information - this affects equity market participants and biotech-focused funds.
  • A leadership transition with the CEO stepping down and the chairman assuming the CEO role introduces execution and governance uncertainty during a critical development phase for the company - relevant to corporate governance and investor confidence in the healthcare sector.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026